CTR-DB 2.0: an updated cancer clinical transcriptome resource, expanding primary drug resistance and newly adding acquired resistance datasets and enhancing the discovery and validation of predictive biomarkers
Nucleic Acids Research · 06.01.2025 · 53 (D1) · D1335-D1347
DOI: 10.1093/nar/gkae993 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 04.11.2024. Verfasst von Jianzhou Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Hebei University, Baoding 071002, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, Biomarkers, Tumor, Transcriptome. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Drug resistance is a principal limiting factor in cancer treatment. CTR-DB, the Cancer Treatment Response gene signature DataBase, is the first data resource for clinical transcriptomes with cancer treatment response, and meanwhile supports various data analysis functions, providing insights into the molecular determinants of drug resistance. Here we proposed an upgraded version, CTR-DB 2.0 (http://ctrdb.ncpsb.org.cn). Around 190 up-to-date source datasets with primary resistance information (129% increase compared to version 1.0) and 13 acquired-resistant datasets (a new dataset type), covering 10 856 patient samples (111% increase), 39 cancer types (39% increase) and 346 therapeutic regimens (26% increase), have been collected. In terms of function, for the single dataset analysis and multiple-dataset comparison modules, CTR-DB 2.0 added new gene set enrichment, tumor microenvironment (TME) and signature connectivity analysis functions to help elucidate drug resistance mechanisms and their homogeneity/heterogeneity and discover candidate combinational therapies. Furthermore, biomarker-related functions were greatly extended. CTR-DB 2.0 newly supported the validation of cell types in the TME as predictive biomarkers of treatment response, especially the validation of a combinational biomarker panel and even the direct discovery of the optimal biomarker panel using user-customized CTR-DB patient samples. In addition, the analysis of users’ own datasets, application programming interface and data crowdfunding were also added.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Life Sciences, Hebei University, Baoding 071002, China.
- State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.
- College of Chemistry and Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Hebei University), Hebei University, Baoding 071002, China.
- School of Basic Medicine, Anhui Medical University, Hefei 230032, China.
- Beijing Cloudna Technology Company, Limited, Beijing 100029, China.
ORCID-Profile: Jianzhou Jiang, Dong Li, Zhongyang Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Jiang, J., Ma, Y., Yang, L., Ma, S., Yu, Z., Ren, X., Kong, X., Zhang, X., Li, D., & Liu, Z. (2025). CTR-DB 2.0: an updated cancer clinical transcriptome resource, expanding primary drug resistance and newly adding acquired resistance datasets and enhancing the discovery and validation of predictive biomarkers. Nucleic Acids Research, 53(D1), D1335-D1347. https://doi.org/10.1093/nar/gkae993
Vancouver
Jiang J, Ma Y, Yang L, Ma S, Yu Z, Ren X, et al. CTR-DB 2.0: an updated cancer clinical transcriptome resource, expanding primary drug resistance and newly adding acquired resistance datasets and enhancing the discovery and validation of predictive biomarkers. Nucleic Acids Research. 2025;53(D1):D1335-D1347. doi:10.1093/nar/gkae993
BibTeX
@article{Jiang2025,
author = {Jiang, Jianzhou and Ma, Yajie and Yang, Lele and Ma, Shurui and Yu, Zixuan and Ren, Xinyi and Kong, Xiangya and Zhang, Xinlei and Li, Dong and Liu, Zhongyang},
title = {CTR-DB 2.0: an updated cancer clinical transcriptome resource, expanding primary drug resistance and newly adding acquired resistance datasets and enhancing the discovery and validation of predictive biomarkers},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {D1},
pages = {D1335--D1347},
doi = {10.1093/nar/gkae993}
}
EUVIMED